Mirtazapine and Methamphetamine Drug-drug Interaction Study
A legfontosabb adatok
- Ki végzi
- San Francisco Department of Public Health
- Hol
- Los Angeles és San Francisco (Egyesült Államok)Mind a 3 helyszín megnézése
- Azonosító
- Állapot
- Befejeződött
- Fázis
- 1. fázis
- Résztvevők
- 15 fő vett részt
- Kezdés
- 2021. máj. 3.
- Befejezés
- 2024. máj. 31.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
- A vizsgált kezelések
- Mirtazapine
- Methamphetamine
- A regiszteradat frissítve
- 2024. szeptember 27.
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Részt vehetnek
A regiszter feltételei, szó szerint
Mind a 22 feltétel megnézéseKevesebb
Ki vehet részt
- English-speaking
- age 18-55 years inclusive
- meet DSM-V criteria for MA use disorder, as diagnosed via SCID
- provide MA-positive urine during screening
- have a resting heart rate of 50-90
- have a systolic blood pressure ≤ of 100-150 mm Hg, and diastolic blood pressure of 45-90 Hg within two days prior to admission
- have a baseline EKG that demonstrates normal sinus rhythm, QTc < 440 msec in men or QTc < 450 msec in women
- have acceptable safety lab data, ALT / AST<3x upper limit nL; est GFR >50
- if female (except females of non-childbearing potential-e.g., at least 1 year post-menopausal or surgically sterile), not pregnant confirmed by negative pregnancy test nor lactating and willing to use a medically approved method of birth control to prevent pregnancy during the trial and for 7 days after the last dose of study medication
- For those who also use opioids and are on methadone maintenance treatment (Group 2), urine positive for methadone and negative for buprenorphine on admission
Ki nem vehet részt
- current ongoing treatment with psychotropic medications (e.g. antidepressants, antipsychotics, antiepileptics, sedative/hypnotics, narcotic analgesics)
- urine positive for MA and other unplanned drugs on the day of admission and breathalyzer results negative for alcohol
- any prior adverse reaction to MA; including chest pain or epileptic seizure
- Have current cocaine, cannabis, or alcohol use disorder by DSM-V SCID
- current or past history of seizure disorder
- major psychiatric disorder not due to substance abuse (e.g., schizophrenia, bipolar illness but excepting stable major depressive disorder, generalized anxiety disorder, etc.) as assessed by the SCID
- have a current neurological disorder (e.g., organic brain disease, dementia) or medical condition which would make study compliance difficult or compromise informed consent
- history of suicide attempt(s) in the past 90 days or current suicidal intent or plan by SCID
- evidence of untreated or unstable serious medical illness including: neuroendocrine, autoimmune, renal, hepatic, or active infectious disease including active tuberculosis infection
- any serious medical or psychiatric AE after test infusion of MA 30mg IV (e.g. sustained SBP>200 or DBP>100; sustained pulse >(220-0.85xAge)
- seeking treatment for MA problems at the time of the study
- any other circumstances that, in the opinion of the investigators, would compromise participant safety and/or successful completion of the trial
Helyszínek itt: Egyesült Államok
- UCLA Medical CenterLos Angeles, Egyesült Államok
- San Francisco Department of Public HealthSan Francisco, Egyesült Államok
- Substance Use Research UnitSan Francisco, Egyesült Államok
A vizsgálatról
Mit akar kideríteni a vizsgálat
This is a drug-drug interaction (DDI) study of mirtazapine for methamphetamine (MA) use disorder (MUD) to ensure the safety of this medication in the presence of a relevant dose of MA for people actively-using MA.
A teljes eredeti leírásKevesebb
Aim 1: To determine if mirtazapine alters the cardiovascular response to IV MA.
Aim 2: To determine if the pharmacokinetics of IV MA are altered by mirtazapine administration.
Aim 3: To evaluate the above aims in the setting of concomitant administration of methadone.
This study involves two simultaneous within-subject drug-drug interaction studies, each comprised of 12 participants. A total of 24 subjects will be enrolled who have methamphetamine use disorder who will be classified into 2 groups: (Group 1: no opioids; Group 2: opioid use disorder on methadone maintenance). Subjects will be randomized to the order of mirtazapine and placebo (i.e. one-half will receive mirtazapine first, then placebo; one-half will receive placebo first, then mirtazapine).
A vizsgálat 2 csoportja
- MirtazapineA vizsgált kezelés
Mirtazapine 30 mg PO daily x 4 days
Kezelés: Mirtazapine és Methamphetamine
- PlaceboPlacebo, összehasonlításként
Placebo 30 mg PO Daily x 4 days
Kezelés: Methamphetamine
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Phase 1 Safety-interaction Study of Mirtazapine for the Treatment of Methamphetamine Use Disorder
- A regiszteradat frissítve
- 2024. szeptember 27.